Statements (15)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:bemarituzumab
|
| gptkbp:approvedBy |
gptkb:European_Union
2023 |
| gptkbp:ATCCode |
L01FX20
|
| https://www.w3.org/2000/01/rdf-schema#label |
Enbihaar
|
| gptkbp:indication |
gastric cancer
gastroesophageal junction adenocarcinoma |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketingAuthorizationHolder |
Amgen Europe B.V.
|
| gptkbp:mechanismOfAction |
FGFR2b receptor antagonist
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:usedFor |
treatment of cancer
|
| gptkbp:bfsParent |
gptkb:Park_Hill_Stakes
|
| gptkbp:bfsLayer |
7
|